News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SIA-Chart on PRAN : UP! UP! and AWAY!!!!
Morning Charles,
A man gotta do what a man gotta do ... 
Make sure you pay us a visit sometimes & Best of luck buddy !
Dan
Thanks Stuffit I'll try my best to keep those alerts coming so we can all make some money together.
BIO. Bio-Rad Launches a Digital Biology Center to Develop Products for Research and Diagnostics Markets Based on the Company's Droplet Digital Technology
http://finance.yahoo.com/news/bio-rad-launches-digital-biology-201000369.html
PRAN. Prana's Parkinson's Drug Meets Michael J. Fox Foundation Development Milestone
PBT434 Advances Through IND Enabling Studies
http://finance.yahoo.com/news/pranas-parkinsons-drug-meets-michael-141500625.html
MELBOURNE, AUSTRALIA--(Marketwire -08/29/12)- Prana Biotechnology Limited (PRAN) (PBT.AX) announced today that its lead compound in development for Parkinson's disease (PD), PBT434, had progressed successfully though a series of preclinical development studies used to assess the suitability of a candidate compound for human clinical studies. The studies were funded by The Michael J. Fox Foundation (MJFF) 2011 Pipeline Program to support its 'Therapeutic Development Initiative.' The MJFF Program grant is milestone based. PBT434 achieved all of its milestones in preclinical toxicology studies, genotoxicity and safety pharmacology -- allowing the compound to be positioned for larger scale animal toxicology studies prior to commencing clinical trials.
PBT434 is a novel, orally available compound that easily crosses into the brain and is able to exert potent neuroprotective properties. Most particularly, it preserves the brain tissue in PD that degenerates over time, the substantia nigra. By preserving this tissue, Prana's scientists have demonstrated significant restoration of motor coordination and strength in animal models. PBT434 has been shown that it is able to impede the iron-induced oxidative damage and neurotoxic cascade that kills the substantia nigra. As such, PBT434's mechanism of action offers a novel disease modifying therapeutic strategy in contrast to the currently marketed symptomatic agents that, at best, serve to reduce the side effects of the disease rather than alter its course.
"Based on these efficacy studies and now the completion of this suite of preclinical development assessments, Prana will look to move PBT434 into longer term toxicology studies in parallel to our scale up manufacturing plans for PBT434. All being well, we could file an IND by the end of next year and commence clinical trials in 2014," said Mr. Geoffrey Kempler, Prana's Executive Chairman. "PBT434 also marks another product pipeline milestone for Prana to complement our two ongoing trials with PBT2 in Alzheimer's disease and Huntington disease," commented Mr. Kempler.
Parkinson's disease is a devastating illness which can result in not only the loss of muscle control, speech, balance and digestive functions; it may also impair a patient's psychiatric and cognitive function. With 4 million people affected worldwide, Parkinson's disease is the second most common neurological indication behind Alzheimer's disease. The current market size for drugs to treat Parkinson's disease is approximately $4 billion per year; however most currently available drugs primarily treat the symptoms and do not actually prevent the ongoing destruction of the substantia nigra in the brain and progression of the disease.
* The program grant title is 'PBT434, a novel neuroprotective drug for Parkinson's Disease; completion of pre-clinical studies to enable human clinical trials.'
ARQL tanker
ArQule plunges 23% on drug safety concern
BOSTON (MarketWatch) -- Shares of ArQule Inc. ARQL -25.69% plunged 23% to $5.15 on Wednesday on safety concerns about its drug candidate tivantinib for the treatment of lung cancer. In a federal filing made Tuesday, ArQule said that its Japanese development partner, Kyowa Hakko Kirin Co., has temporarily suspended a Phase III clinical trial testing tivantinib in combination with the lung-cancer therapy Tarceva over concerns that some of the patients had developed interstitial lung disease. As of Wednesday, shares of ArQule are down 9% from the start of the year.
WCRX down 22%
SBX / ESGR News
Seabright Insurance Holdings to be acquired by Enstar Group (ESGR) for $11.11 per share (SBX) 8.27 : Enstar Group (ESGR) and SeaBright Holdings (SBX) jointly announce that they have entered into a definitive merger agreement under which Enstar will acquire SBX for $11.11 per share in cash. The purchase price represents a 34.3% premium over SBX's closing price. ESGR expects to finance the aggregate purchase price of ~$252 mln through a combination of cash on hand and a bank loan facility to be finalized before closing.
MDCO. before-open. Latest European Heart Attack Treatment Guidelines Recommend Angiomax(R)/Angiox(R) (Bivalirudin) Over Heparin
http://finance.yahoo.com/news/latest-european-heart-attack-treatment-050000838.html
MUNICH, GERMANY--(Marketwire -08/28/12)- Updated treatment guidelines presented by a leading European acute cardiology expert task force on the management of a severe form of heart attack called ST-segment elevation acute myocardial infarction (STEMI) recommend the use of bivalirudin (The Medicines Company (MDCO) trade name Angiox® in Europe and Angiomax® in North America and Asia) over heparin and a GP IIb/ IIIa blocker.
According to the guidelines, an anticoagulant "must be used" in patients undergoing primary percutaneous coronary intervention (PCI), an emergency lifesaving procedure used to unblock coronary arteries and restore blood flow to the heart muscle in a heart attack. The experts nominated Angiox as the Class I first choice "recommended over unfractionated heparin and a GP IIb/IIIa blocker."
The guidelines, presented as part of the European Society of Cardiology (ESC) annual congress in Munich this week, were developed by a 23 member expert Task Force on Myocardial Revascularization of the European Society of Cardiology. The guidelines provide recommendations for the management of heart attack patients from diagnosis to treatment, and are used by health care teams across Europe.
Bivalirudin was recognized by the expert panel as having both the highest strength of recommendation and level of evidence from clinical research (Class I, level of evidence B) of any intravenous antithrombotic listed in the updated guidelines.
Efthymios Deliargyris, MD, Global Medical Director for The Medicines Company, commented, "Over the last years, great strides have been made in the management of STEMI. Compared to a few years ago, thanks to advances in treatment techniques, technologies and medicines available for use in patients with STEMI, the risk of dying has been markedly reduced."
Cees Heiman, Senior Vice President and Regional Engagement Leader for Europe and the Middle East for The Medicines Company said, "Since the last guideline update in 2010, several milestones regarding Angiox and The Medicines Company in Europe have occurred. Most notably, in June 2011, The Lancet published the final three year results of a clinical trial called HORIZONS-AMI that was conducted globally in 3,602 STEMI patients undergoing primary PCI. We welcome these latest updates to the guidelines, as they will help health care teams make informed decisions in providing the best care for their patients."
September FDA plays
>>> Link back for August plays
09/05/2012 Novartis AG NVS Tobramycin inhalation powder (NDA)
FDA panel to review Tobramycin inhalation powder for mgmt of cystic fibrosis patients infected with Pseudomonas aeruginosa
09/05/2012 Salix Pharmaceuticals Ltd SLXP Crofelemer 125 mg tablets (NDA)
FDA decision on Crofelemer for control and symptomatic relief of diarrhea in patients with HIV/AIDS on anti-retroviral therapy
09/09/2012 Ironwood Pharmaceuticals, Inc. IRWD Linaclotide (NDA)
FDA decision on Linaclotide for treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation
09/10/2012 Navidea Biopharmaceuticals, Inc. NEOP, NAVB Lymphoseek (NDA)
FDA decision on Lymphoseek for proposed use in intraoperative lymphatic mapping
09/13/2012 Cornerstone Therapeutics Inc. CRTX Lixivaptan (CRTX 080) (NDA)
FDA panel to review Lixivaptan for treatment of hyponatremia
09/14/2012 Gilead Sciences Inc. GILD Truvada (sNDA)
FDA decision on Truvada in new indication as HIV preventive therapy
*FDA approved Truvada as HIV preventive therapy on Jul.16
09/30/2012 NPS Pharmaceuticals Inc NPSP Gattex (NDA)
FDA decision on Gattex for proposed treatment of adult short bowel syndrome
*FDA decision date postponed to Dec.30, 2012
SDY. S&P Dividend Fund. 3 year chart.
STX. Seeking Alpha. Why Seagate Looks More Compelling Than Apple
August 27, about: STX, includes: AAPL, SDY
http://seekingalpha.com/article/831061-why-seagate-looks-more-compelling-than-apple
Seagate Technology (STX) is a $13.53 billion large-cap Ireland-based company that manufactures hard disk drives. In addition to being used in desktop and notebook computers, Seagate's products are also used in enterprise servers, mainframes, workstations, DVRs, game consoles, personal data backup systems, portable external storage systems, and digital media systems. The company also provides various data storage services.
Seagate has a compelling undervaluation with a trailing P/E ratio of 5.25, a forward P/E ratio of 4.88, and a PEG of 0.16. The stock price has not kept pace with the company's earnings. This is a positive characteristic as the stock will continue to gravitate toward the company's earnings growth.
The company has a high profit margin of 19.16% and an operating margin of 20.98%. For the past 12 months, Seagate has pulled in $3.26 billion in operating cash flow and $1.61 billion in free cash flow. The company has 1.87 times more current assets than current liabilities.
Although the company missed earnings estimates by 4% in its most recent quarter, it beat estimates for the previous three quarters. The company also had record revenue of $4.5 billion and record shipments of 66 million units for the quarter. This comprised a market share of approximately 42%.
Seagate is expected to grow earnings annually at a high rate of 28.28% for the next five years. When you combine the company's generous dividend of 3.8%, investors have the potential to triple the performance of the average S&P 500 company. If this 32% CAGR is realized by reinvesting dividends, a $10,000 investment in Seagate could be worth $40,000 in five years.
Seagate currently looks more compelling than Apple (AAPL) in terms of valuation and growth. Let's take a look at a side-by-side comparison of these two companies.
Granted, the two companies are different in terms of the type of technology that they produce. However, when we compare them as potential investments, what matters is a good entry point and the potential earnings growth. When looking at valuation in terms of P/E and PEG ratios, we can see that Seagate presents a much lower valuation than Apple. Since Seagate is operating in the eurozone, the stock has been unfairly suppressed and has not caught up to its earnings growth. Apple also tends to grow earnings at a faster rate than its stock appreciation rate, keeping it undervalued.
Seagate's dividends are more than twice as generous as Apple's. With a 3.8% dividend, Seagate's yield is even higher than the SPDR S&P 500 Dividend Aristocrats (SDY) average of 3.22%. However, Seagate has not been as consistent as the dividend aristocrats in raising dividends over time. Therefore, the stock should be viewed more as a growth company than a dividend-paying company, in my opinion.
It is quite compelling for both Apple and Seagate to be undervalued and also have expected earnings growth above 20%. Some may argue that Apple's expected growth of 22.26% is too low, and that may turn out to be true. If Seagate can achieve its expected annual growth of 28.28%, the stock should continue to perform well. Seagate's stock performance may even surpass Apple's stock performance since it currently has a lower valuation and a higher expected earnings growth rate. Overall, both companies should continue to perform well above average for the next five years. With Apple getting a lot of attention in the investing world, I thought that Seagate also deserves a serious look.
Disclosure: I am long AAPL. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
David Zanoni.
|
Followers
|
2
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
531
|
|
Created
|
07/24/12
|
Type
|
Free
|
| Moderators | |||
AI
